President and Chief Executive Officer
Russell H. Plumb served as the Vice President, Finance and Administration and Chief Financial Officer from August 2000 until December 2006, when he was named President and Chief Executive Officer. From December 1999 to July 2000, Mr. Plumb served as Chief Financial Officer of Emory Vision, a healthcare company. From 1994 to November 1999, he served as Chief Financial Officer and Vice President, Finance of Serologicals Corporation, a publicly-held biopharmaceutical company. Mr. Plumb received both a B. Comm. and a M.B.A. from the University of Toronto. Mr. Plumb has received designations as a certified public accountant in Michigan and Georgia.

Co-Founder, Chief Scientific Officer and Senior Vice President of Research and Development
Joseph M. Patti, M.S.P.H., Ph.D. is a co-founder of Inhibitex, Inc. and has served as the Vice President, Preclinical Development and Chief Scientific Officer of the Company since April 1998 and Vice President of Research and Development since 2005. From 1994 to 1998, Dr. Patti was an assistant professor at Texas A&M's Institute of Biosciences and Technology. From 1996 to 1998, he served on the faculty at the University of Texas Health Science Center Graduate School of Biomedical Sciences. He currently holds an adjunct faculty position in the biology department at Georgia State University. Dr. Patti received a B.S. in Microbiology from the University of Pittsburgh, an M.S.P.H. from the University of Miami, School of Medicine and a Ph.D. in Biochemistry from the University of Alabama at Birmingham.

Senior Vice President of Drug Development
Geoffrey Henson, PhD joined Inhibitex as Senior Vice President of Drug Development in 2007. Previously he served as CEO, President and Secretary of FermaVir Pharmaceuticals, Inc. from 2005 to 2007. From 2003 to March 2005, Dr. Henson was a pharmaceutical consultant. He was a founder and Chief Operating Officer of AnorMED, a Canadian biopharmaceutical company from 1996-2003. Prior to that, he held a number of management and scientific positions in the Biomedical Research Group at Johnson Matthey from 1985-1996. From 1982-1985, Dr Henson was a researcher and member of the Basel Institute for Immunology in Basel, Switzerland. From 1978-1981, Dr. Henson did post-doctoral research at the Roswell Park Memorial Cancer Institute. Dr. Henson obtained his M.S. and Ph.D. in Biochemistry from New Mexico State University, and B.S. in Chemistry from Dickinson College.

Vice President of Clinical Development
Amy Morris has served as Vice President of Clinical Development since 2006. She joined Inhibitex in 2002 as a Director of Clinical Development and the Veronate Project Leader. From 1994 to March 2002, Ms. Morris held several senior management positions at the contract research organization, Clinimetrics Research Associates, Inc., including Senior Vice President responsible for East Coast and Global Operations. From 1989 to 1994 she served as the Executive Director of the AIDS Research Consortium of Atlanta, a non-profit clinical and epidemiological research organization. From 1986 to 1989 she held clinical research positions at bio-pharmaceutical companies Triton Biosciences, Inc. and Boehringer Ingelheim, Inc. From 1982 to 1984 she served as the Clinical Coordinator for the University of California, San Francisco, Drug Studies Unit. Ms. Morris received a B.S. in Biology from St. Mary's College Notre Dame, and an M.B.A. in Management from Georgia State University.

Director, Monoclonal Antibody Development
Jeff Hutchins, Ph.D. has served as Director of Monoclonal Antibody Development since January 2001. From 1991 through 2000 he held several Senior Scientist positions in Discovery Research at Glaxo Wellcome with a visiting professor appointment in the Department of Biochemistry at Rush Medical College. Dr. Hutchins received a B.S. in Biology from Oral Roberts University, a Ph.D. in Biomedical Sciences from the University of Texas, Health Science Center at Houston – Graduate School of Biomedical Sciences and postdoctoral training from University of Southern California – Department of Microbiology. Dr. Hutchins publications and patents span the fields of infectious disease, immunology, oncology and osteoarthritis.

Senior Director of Biological Sciences
John Vernachio, Ph.D. has served as Senior Director of Biological Sciences, since January 2004 and as Director, Biological Resources from1998 to 2004. From 1997 to 1998, Dr. Vernachio held several management positions with Valentis, Inc. including Director of Life Sciences. He was a member of the Gene Therapy Unit of Baxter Healthcare Corp. from 1991 to 1997, where he served as Manager of Molecular Immunology. Dr. Vernachio received a B.S. in Animal Sciences from the University of Vermont, a Ph.D. in Biochemistry from the Johns Hopkins University School of Medicine and was a post-doctoral fellow in the Department of Immunology at the Research Institute of Scripps Clinic.

Director of Finance
Peter Azzarello has served as Director of Finance since 2004. Prior to joining Inhibitex, Mr. Azzarello served as Associate VP of Financial Reporting for NetBank from 2001 to 2003. From 1994 to 2000 he held senior financial positions with several private and publicly traded companies including, Metavante, a subsidiary of Marshall & Ilsley, ProxyMed, Grand Adventures Travel, and G.L. Homes. Mr. Azzarello received a B.A. in Accounting and Finance from Florida Atlantic University and is a certified public accountant.